Supernus Pharmaceuticals, Inc. (SUPN) stock prices updated...
 

Supernus Pharmaceuticals, Inc. stock price

Supernus Pharmaceuticals, Inc. latest news:


  • 09/18/2017 15:50:50

    Supernus shares decline on drug study change

    Supernus Pharmaceuticals Inc. shares declined late Monday after the drug maker said it has altered a study of a child aggression treatment under advice from a third-party statistician. Supernus shares declined 5.5% to $46.91 following a brief halt after hours. The company said it has decided to eliminate a low-dose, or 18 mg, option of its SPN-810 drug to treat impulsive aggression in children aged 6 to 12 years who have attention deficit hyperactivity disorder, while keeping the higher, 36 mg dose in the studies. The decision to make the change came from an early analysis from an independent third-party statistician, the company said. "Moving forward, all patients will be randomized to either the 36 mg dose arm or placebo until the predetermined total number of patients are enrolled without changing the size of the trials," Supernus said in a statement, adding that it "believes that this will maximize the probability of reaching a statistically significant outcome for the 36 mg dose."Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    support.com, Inc.SPRT | Surgical Care Affiliates, Inc.SCAI | SurModics, Inc.SRDX | Sussex BancorpSBBX | Sutor Technology Group LimitedTOR | SVB Financial GroupSIVB | SVB Financial GroupSIVBO | Swisher Hygiene, Inc.SWSH | Sykes Enterprises, IncorporatedSYKE | Symantec CorporationSYMC |